PET-CT in pediatric Langerhans cell histiocytosis.
Our objective was to assess the utility of PET-CT in five pediatric patients with Langerhans cell histiocytosis (LCH) who underwent PET-CT imaging for clinical staging and determination of lesion activity at various stages of treatment and follow-up. PET-CT combines the anatomic detail of CT and the physiologic activity of (18)F-FDG imaging. We conclude that PET-CT information is clinically useful to evaluate disease activity and response to therapy and provides information that cannot be obtained from technetium 99m methylene diphosphonate bone scans or radiographs.
Kaste
Sue C
SC
Division of Diagnostic Imaging, Department of Radiological Sciences, St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38105-2794, USA. sue.kaste@stjude.org
Rodriguez-Galindo
Carlos
C
McCarville
Mary E
ME
Shulkin
Barry L
BL
D002648:Child; D002675:Child, Preschool; D005260:Female; D019788:Fluorodeoxyglucose F18; D006646:Histiocytosis, Langerhans-Cell / Q000000981:diagnostic imaging*; D006801:Humans; D007223:Infant; D008297:Male; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18